Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting
LEIDEN, Netherlands, April 1, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces new data from the pivotal Phase II/III trial of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a primary immunodeficiency. Principal Investigator V. Koneti Rao, M.D., a staff...
REDUCE LAP-HF II ANALYSES SHOW 50% OF STUDY PATIENTS DEMONSTRATED SIGNIFICANT CLINICAL BENEFIT FROM THE CORVIA® ATRIAL SHUNT
Landmark trial advances understanding of which HFpEF patients may benefit from atrial shunt therapy TEWKSBURY, Mass., April 1, 2022 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), announced publication of analyses from its global, phase III REDUCE LAP-HF II randomized trial of...
Zhongze Therapeutics Announces Successful Completion Of The First-In-Human Dose Escalation Study of ZZ6398 in Healthy Volunteers
SHANGHAI, April 1, 2022 /PRNewswire/ -- Zhongze Therapeutics, a clinical stage biotech company focused on the discovery, development and commercialization of innovative and transformative therapies for both psychiatric and neurological disorders announced today the successful completion of the first-in-human dose escalating study of ZZ6398 (SIPI6398) in healthy volunteers. "We are thrilled that top line results indicate ZZ6398 is safe and...
Korea Ginseng Corp. Launches KORESELECT Line in the U.S. Market
- World's No.1 Ginseng Brand launched exclusive brand "Koreselect" for the U.S.- Lee Min-ho, Global Embassador of KGC, plays the role in Pachinko on Apple TV+ SEOUL, South Korea and NEW YORK, April 1, 2022 /PRNewswire/ -- Korea Ginseng Corporation (KGC), the world's number one ginseng brand, officially launched its KORESELECT product...
Akeso Reported 2021 Annual Results
Penpulimab Started Commercialization and Cadonilimab Filed for NDA HONG KONG, April 1, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, reported 2021 annual results. Highlights: Anniko® (Penpulimab, AK105, PD-1) obtained market entry approval from the Chinese National Medical...
Venus Medtech announces 2021 annual results: pacesetter in China and breakthrough-maker worldwide
HANGZHOU, China, April 1, 2022 /PRNewswire/ -- On March 31, 2022, Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as "Venus Medtech"), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced its annual results for the year ended December 31, 2021. According to the financial report, Venus Medtech recorded RMB416 million in...
UMP Healthcare Expands Free Telemedicine and Drug Delivery to COVID-19 Patients
Charity Foundation Receives HK$1 million Donation from CTFE Social Solutions * * * Demand for Telemedicine Increases and Expects to be a New Trend in Medical Services Nearly 90% of Users are Willing to Recommend the Services to Relatives and Friends HONG KONG, April 1, 2022 /PRNewswire/ -- UMP Healthcare Holdings Limited ("UMP" or the "Group", SEHK: 722)...
Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase — Clinical Trial of CB06
SHANGHAI, March 31, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), an innovation-driven biopharmaceutical company focused on the development of innovative drugs for the treatment of chronic hepatitis B and central nervous system diseases, announced dosing of the first participant in the US Phase I study of its novel TLR8 agonist (CB06), which is being developed for the...
Aceemzyme Co., Ltd., challenging to new drug of brain diseases with recombinase-based ginsenoside Rh2 (s) mass production technology…
- Under development of ginsenoside Rh2(s) mass production technology… - "Enhanced production of ginsenoside Rh2(S) from PPD-type major ginsenosides using BglSk cloned from Saccharibacillus kuerlensis together with two glycosidase in series" SOUTH KOREA, Seoul, March 31, 2022 /PRNewswire/ -- Ginsenosides Minute amounts of rare ginsenoside that present in ginseng show different efficacy depending on position where glucose residue...
NCCN Annual Conference Focuses on Cancer Patient Journey; with Cutting-Edge Research and Latest Evidence-Based Care Recommendations
Three-day #NCCN2022 virtual oncology conference from National Comprehensive Cancer Network includes didactic presentations, interactive discussions, and challenging case reviews. PLYMOUTH MEETING, Pa., March 31, 2022 /PRNewswire/ -- The NCCN 2022 Annual Conference brings together more than a thousand oncology professionals from around the world to learn about the latest evidence-based treatment recommendations...
